D. Frye

Medicine · Health Sciences

13h-index2.5kcitations29works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(20), Breast Cancer Treatment Studies(16), HER2/EGFR in Cancer Research(6), Chemotherapy-related skin toxicity(5), Chemotherapy-induced cardiotoxicity and mitigation(4)

Publications28 total

HER2 expression and efficacy of preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, doxorubicin chemotherapy in breast cancer
Journal of Clinical Oncology·2007
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers
Annals of Oncology·2007· 74 citedOpen Access
Twelve-year follow-up of a randomized trial of high-dose chemotherapy (HDC) and autologous hematopoietic stem cell support (ASCS) for high-risk primary breast carcinoma
Journal of Clinical Oncology·2005· 3 cited
Invasive lobular carcinoma (ILC) “classic type”: Distinct clinical features
Journal of Clinical Oncology·2004· 4 cited
Invasive lobular carcinoma (ILC) “classic type”: Distinct clinical features
Journal of Clinical Oncology·2004· 2 cited
Readers question whether drug increases side effects of chemotherapy.
PubMed·1999
Capecitabine: nursing implications of a new oral chemotherapeutic agent.
PubMed·1999· 44 cited
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results
Annals of Oncology·1999· 23 citedOpen Access
Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy
Annals of Oncology·1998· 37 citedOpen Access
Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
PubMed·1997· 11 cited
Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.
Journal of Clinical Oncology·1997· 155 cited
Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.
Journal of Clinical Oncology·1996· 124 cited
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.
Journal of Clinical Oncology·1996· 753 cited
Second-line chemotherapy for metastatic breast cancer including quality of life issues
The Breast·1996· 7 citedOpen Access
Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer.
Journal of Clinical Oncology·1994· 14 cited
Taxol in metastatic breast cancer: the MD Anderson Cancer Center experience
Cancer Treatment An Update·1994
Primary chemotherapy for breast cancer: response to preoperative chemotherapy as prognostic factor
Cancer Treatment An Update·1994· 1 cited
The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer.
PubMed·1993· 49 cited
Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer
JNCI Journal of the National Cancer Institute·1991· 745 cited
Lack of correlation between histologic findings and response to chemotherapy in metastatic breast cancer
Cancer·1991· 8 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Aman U. Buzdar(18), Gabriel N. Hortobágyi(12), Vicente Valero(8), Richard L. Theriault(8), Frankie A. Holmes(7), Giuseppe Fraschini(7), G. N. Hortobagyi(6), G. N. Hortobágyi(5), A. U. Buzdar(4), Shu‐Wan Kau(4), Ana M. González-Angulo(4), R S Walters(3), Daniel J. Booser(3), Terry L. Smith(2), L. D. Ziegler(2), R. Theriault(2), Verena Hug(2), Tom L. Smith(2), Lina Asmar(2), Richard E. Champlin(2)